October 11, 2026
FDA Accepts Vamikibart BLA for Uveitic Macular Edema
New phase 3 data presented at AAO 2026 showed sustained visual and anatomic improvements through 52 weeks in the MEERKAT and SANDCAT trials.
2026 AAO Meeting
Related Content
October 11, 2026
Remigromig Meets Primary Endpoint in BRUNELLO Trial
Both doses of the Wnt pathway agonist met the primary noninferiority endpoint in evaluation against ranibizumab in patients with DME, Donald J. D’Amico, MD, reported at AAO.
October 10, 2026
Two-Year PRISM Data Show Reduced Treatment Burden
Veeral Sheth, MD, discusses the durability, safety, and supplemental injection requirements of intravitreal 4D-150 gene therapy for wet AMD.
October 10, 2026
Early ELAAVATE Data Show Promise in DME
Arshad M. Khanani, MD, FASRS, discusses preliminary safety and efficacy findings from a phase 2 study of subretinal sura-vec gene therapy.
October 10, 2026
Tarcocimab and Tabirafusp Meet Phase 3 Endpoints
At AAO 2026, Charles C. Wykoff, MD, PhD, presented positive DAYBREAK results for both Kodiak Sciences agents. A BLA submission for tarcocimab is planned later this year.
October 10, 2026
K8 Shows Greater GA Growth Reduction Over Time
Liangbo Shen, MD, reported additional phase 2 findings at AAO 2026 as Inflammasome Therapeutics prepares for a phase 3 trial.